ArticleCureus2025
miR-145-Mediated Tumor Suppression in Bladder Urothelial Carcinoma via Targeting the ADAMTS5/Wnt Signaling Axis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder urothelial carcinoma (BLCA) is the most common urological tumor with high mortality. The present study aimed to investigate the role of miR-145 in the tumorigenesis of BLCA. MATERIALS AND
methodsThe levels of miR-145 and ADAMTS5 were examined in BLCA specimens. BLCA cell lines T24 and 5637 were adopted for in vitro experiments. ADAMTS5 was verified as a downstream target of miR-145 using a luciferase reporter assay. Cell viability and apoptosis were detected using the CCK-8 assay and flow cytometry. Cell migratory and invasive capacities were examined by the transwell assay. The protein levels of ADAMTS5, E-cadherin, N-cadherin, and vimentin were analyzed by western blotting.
resultsmiR-145 was found to be negatively correlated to the expression of ADAMTS5 in BLCA specimens. ADAMTS5 was identified as a direct target of miR-145. In addition, PCR and western blotting showed that miR-145 overexpression reduced ADAMTS5 levels, suppressed cell viability, and induced cell apoptosis, whereas miR-145 knockdown triggered the opposite result. miR-145 has also been verified to impede epithelial-mesenchymal transition (EMT) activation in tumor progression.
conclusionThe present study revealed that miR-145 negatively regulates the expression of ADAMTS5. This regulatory effect of miR-145 may be associated with the Wnt/β‑catenin signaling pathway. Therefore, miR-145 has the potential to be used as a biomarker for predicting the progression of BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.